Ardent Health, Inc. (ARDT) Stock Price & Analysis
Ardent Health, Inc. (ARDT) closed at USD 12.36 on Thursday, October 22, 2026, up 2.49% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.06; the Oct 22, 2026 session ranged USD 12.05–12.37 on volume of 330,719 shares. Market capitalization is $1.74B, with a 52-week range of USD 7.71–15.48 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARDT.md
Key facts (ARDT)
- Last four reported quarters (through Jun 30, 2026): revenue $6.41B, net income $78.2M (1.2% margin) (SEC filings).
- Valuation: P/E 22.3x (avg 10.0x at the last 2 fiscal year-ends), net debt $377M.
- Analysts: Hold (mean 2.54 on a 1–5 scale) (13 analysts), mean target USD 12.67 (range 10.5–14).
- Total return with dividends: 1Y -16.5% vs S&P 500 +14.9%; 5Y -28.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.25, revenue estimate $1.60B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARDT)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $5.13B | $5.41B | $5.97B | $6.32B | $6.41B |
| Net income | $189M | $53.9M | $210M | $136M | $78.2M |
| EPS (diluted) | $1.50 | $0.43 | $1.58 | $0.96 | — |
| Net margin | 3.7% | 1.0% | 3.5% | 2.1% | 1.2% |
| Revenue growth | — | +5.5% | +10.3% | +6.0% | — |
| Cash + short-term investments | $456M | $438M | $557M | $710M | — |
| Total debt | — | $1.19B | $1.11B | $1.12B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARDT)
P/E 22.3x · P/S 0.3x · EV/Sales 0.3x · P/B 1.3x · Earnings yield 4.49% · Net debt $377M · EV $2.12B
P/E at fiscal year-ends: Dec 2025 9.2x, Dec 2024 10.8x.
Analysts (ARDT)
Consensus Hold (mean 2.54 on a 1–5 scale), 13 analysts; mean target USD 12.67 (low 10.5, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | BMO Capital | Initiated | Market Perform | $11 |
| 2026-09-18 | Leerink Partners | Maintained | Outperform | $14 |
| 2026-08-10 | RBC Capital | Target raised | Outperform | $12 → $13 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $12 → $13 |
| 2026-08-06 | Guggenheim | Target raised | Buy | $13 → $14 |
| 2026-07-14 | Truist Securities | Target lowered | Buy | $13 → $12 |
| 2026-07-09 | RBC Capital | Target lowered | Outperform | $13 → $12 |
Total return (dividends reinvested) (ARDT)
| 1Y (from 2025-10-23) | 5Y (from 2024-07-15) | |
|---|---|---|
| Total return | -16.5% | -28.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -16.6% | -13.8% |
| Volatility (annualized) | 59.4% | 51.2% |
| Max drawdown | -48.5% (Oct 2025→Jun 2026) | -58.8% (Aug 2024→Jan 2026) |
ARDT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.24 | $0.25 | -3.0% | $1.60B | 4 |
| Next quarter (ends Dec 2026) | $0.34 | $0.43 | -19.3% | $1.63B | 4 |
| Current fiscal year (ends Dec 2026) | $1.09 | $1.29 | -15.7% | $6.46B | 4 |
| Next fiscal year (ends Dec 2027) | $1.25 | $1.25 | +0.8% | $6.73B | 4 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 12.36 |
|---|---|
| Change | ▲ 2.49% (up) |
| Previous Close | USD 12.06 |
| Open | USD 12.14 |
| Day Range | USD 12.05 – 12.37 |
| 52-Week Range | USD 7.71 – 15.48 |
| Volume | 330,719 shares |
| Market Cap | $1.74B |
| Exchange | NYQ |
Technical Analysis (ARDT)
Nexqual's technical model rates ARDT "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.31 (neutral) |
| vs SMA50 | Above (USD 11.01) |
| MACD | 0.39 (positive) |
Analyst Ratings (ARDT)
Wall Street analysts rate ARDT "Hold" based on 13 analysts, with a mean price target of USD 12.67 (range USD 10.5–14), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 12.67 |
| High Target | USD 14 |
| Low Target | USD 10.5 |
| Buy / Hold / Sell | 7 / 5 / 1 |
Earnings (ARDT)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.25 |
| Revenue Estimate | $1.60B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.27 vs est 0.19 ▲ beat |
| 2026-03-31 | USD 0.3 vs est 0.18 ▲ beat |
| 2025-12-31 | USD 0.36 vs est 0.35 ▲ beat |
| 2025-09-30 | USD 0.83 vs est 0.42 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (ARDT)
| Total Revenue | $6.41B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -1.40% |
| Gross Margin | +58.38% |
| Operating Margin | +3.44% |
| Profit Margin | +1.22% |
| ROE | +9.96% |
| Debt / Equity | 1.3 |
| Current Ratio | 2.11 |
| Total Cash | $724.48M |
| Total Debt | $2.27B |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (ARDT)
Nexqual rates Ardent Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 58%, operating 3% (last 12 months) |
| Balance Sheet | Mixed — $724M cash and investments vs $1.10B debt (Jun 2026, SEC) |
| Cash Flow | Solid — Operating cash flow $471M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — ROE 10%, ROA 3.1% |
Ownership (ARDT)
| Insider Ownership | +23.84% |
|---|---|
| Institutional Ownership | +76.82% |
| Shares Outstanding | 141.05M |
| Float | 21.76M |
| Short % of Float | +14.96% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (ARDT)
Ardent Health, Inc. is led by David Caspers, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President, CEO & Director | David Caspers |
|---|---|
| Chief Financial Officer | Alfred Lumsdaine C.P.A. |
| Chief Technology Officer | Lonnie Garrison PMP |
| Senior Vice President of Investor Relations | David Anthony Styblo C.F.A. |
| Regional President of Oklahoma Region | Kevin J. Gross FACHE |
Major Backers & Investors (ARDT)
Notable institutional backers of Ardent Health, Inc. include Ventas Inc, Ameriprise Financial, Inc., Goldentree Asset Management LP, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ventas Inc | 6.62% |
| Ameriprise Financial, Inc. | 1.5% |
| Goldentree Asset Management LP | 1.12% |
| AQR Capital Management, LLC | 1.03% |
| Castleknight Management LP | 0.76% |
| Bridgeway Capital Management, LLC | 0.6% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.54% |
| Columbia Threadneedle | 1.05% |
| Vanguard Group | 0.68% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMN | AMN Healthcare Services Inc | USD 46.82 | ▲ 8.86% |
| HCSG | Healthcare Services Group, Inc. | USD 24.79 | ▲ 14.19% |
| SNDA | Sonida Senior Living, Inc. | USD 33.87 | ▲ 1.2% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
| ASTH | Astrana Health Inc. | USD 38.01 | ▲ 1.77% |
| AGL | agilon health, inc. | USD 90.29 | ▼ 0.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt